

Supplementary Table 2. Treatment Summaries of the Study Patients

Characteristics	Pemetrexed based (n=48)	Non-pemetrexed-based (n=78)	p value
First-line cytotoxic treatment, n (%)			
Pemetrexed/cisplatin	41 (32.5)		
Pemetrexed monotherapy	7 (5.6)		
Gemcitabine+cisplatin/carboplatin		62 (49.2)	
Gemcitabine monotherapy		2 (1.6)	
Irinotecan/cisplatin		1 (0.8)	
Paclitaxel/cisplatin (carboplatin)		12 (9.5)	
Vinorelbine monotherapy		1 (0.8)	
ALKi			
Exposure to ALKi, n (%)	43 (89.6)	73 (93.6)	0.267
Number of ALKi (mean±SD)	1.2±0.6	1.3±0.5	0.181
Exposure to 2nd generation ALKi, n (%)	16 (33.3)	27 (34.6)	0.848
Ceritinib	12 (25.0)	15 (19.2)	
Alectinib	1 (2.1)	6 (7.7)	
Brigatinib	3 (6.3)	6 (7.7)	
ALKi after PD, n (%)	14 (29.2)	31 (39.7)	0.190
Overall pemetrexed exposure, n (%)	48 (100.0)	50 (64.1)	<0.001
Initial intracranial metastasis, n (%)	16 (33.3)	16 (20.5)	0.108
Local treatment	12 (75.0)	7 (43.8)	
Systemic chemotherapy	4 (25.0)	9 (56.2)	

ALK, anaplastic lymphoma kinase; SD, standard deviation; ALKi, anaplastic lymphoma kinase inhibitor; PD, progressive disease.